Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quanterix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quanterix's regulatory disclosures and financial reporting.
Quanterix Corporation reported results from its 2025 Annual Meeting of Stockholders held on September 29, 2025. Stockholders elected Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David R. Walt, Ph.D. to three-year terms on the board of directors, each receiving more than 29.7 million votes in favor.
Investors also approved, on an advisory basis, the compensation of the company’s named executive officers, with about 30.3 million votes for and 5.5 million against. KPMG LLP was ratified as independent registered public accounting firm with over 40.0 million votes for and minimal opposition.
Stockholders backed several governance changes. They approved an amendment to declassify the board of directors and separate amendments to remove supermajority stockholder vote requirements to change certain charter provisions and the company’s bylaws, each receiving approximately 35.6 million votes in favor.
Quanterix Corporation adjourned its shareholder meeting and scheduled an adjourned session for shareholders who pre-register by 10:00am ET on September 28, 2025 at the provided registration URL. The company reported that at the original meeting time shareholders who voted were overwhelmingly in favor of two proposals to eliminate supermajority vote requirements, with 99% of votes cast supporting those two proposals. However, the shares that voted in favor represented 74.8% of the company’s common stock outstanding. The filing is signed by Vandana Sriram, Chief Financial Officer, and lists contact and filing references.
Quanterix Corporation filed an amendment to a current report to provide additional financial details related to its acquisition of Akoya Biosciences, Inc. The acquisition of Akoya was completed on July 8, 2025 under an Amended and Restated Agreement and Plan of Merger dated April 28, 2025 among Quanterix, a merger subsidiary, and Akoya.
This amendment adds unaudited pro forma condensed combined financial statements for Quanterix and Akoya for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025, which are included as Exhibit 99.1. The historical financial statements of Akoya were previously filed in a post-effective amendment to Quanterix’s Form S-4 registration statement and are incorporated by reference rather than repeated here.
Sriram Vandana, Chief Financial Officer of Quanterix Corporation (QTRX), reported a sale of common stock on 09/15/2025. The filing shows 229 shares disposed at a price of $4.97 per share, marked with code F and explained as shares withheld by the company to cover tax obligations arising from the vesting of 777 restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 86,971 shares, which the filing notes includes 71,670 RSUs. The form is signed by an attorney-in-fact on behalf of the reporting person and reflects a routine tax-withholding disposition rather than an open-market sale for cash.
Toloue Masoud, who serves as President & CEO and a director of Quanterix Corporation (QTRX), reported a sale of 1,242 shares of common stock at $4.97 per share. The filing states these shares were disposed (code F) and that 3,722 restricted stock units vested, with shares withheld solely to cover tax obligations related to that vesting. After the reported transaction Masoud is shown as beneficially owning 513,192 shares in total, which include 224,330 restricted stock units.
Quanterix Corp (QTRX) insider purchase by CFO: The filing shows Sriram Vandana, Chief Financial Officer, acquired 4,150 shares of Quanterix common stock on 09/12/2025 at $4.79 per share. After the transaction Vandana beneficially owned 87,200 shares in total, which the filing notes includes 72,447 restricted stock units. The Form 4 was submitted with a signature executed by an attorney-in-fact on 09/15/2025. The document records a single non-derivative purchase and lists no derivative transactions or additional amendments.
Form 4 for Quanterix Corp (QTRX) shows Toloue Masoud, President & CEO and a director, reported transactions dated 08/31/2025. The filing records a disposition of 254 shares of common stock at $4.55 per share. The disposition reflects shares withheld by the company to cover tax obligations upon the vesting of 761 restricted stock units (RSUs). After the reported transaction, Masoud beneficially owns 514,434 shares, which include 228,052 RSUs. The form was signed by an attorney-in-fact on 09/03/2025.
Quanterix Corporation (QTRX) will hold a virtual 2025 Annual Meeting at 9:00 a.m. ET on September 23, 2025, with a record date of July 31, 2025 and 46,465,915 shares outstanding. The Proxy Statement asks stockholders to vote on six proposals: election of three directors (Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David Walt, Ph.D.), an advisory vote on executive compensation, ratification of KPMG LLP as independent auditors for 2025, and three Charter amendments to declassify the Board and remove supermajority vote requirements for certain Charter and Bylaw amendments. The filing discloses the closing of the Akoya Biosciences acquisition on July 8, 2025 and related board changes with appointments of former Akoya directors. The Company entered a Cooperation Agreement with Kent Lake Partners on August 4, 2025, including commitments to appoint a new independent director by December 1, 2025 and to seek Board declassification. Voting procedures, quorum, and broker voting limitations are described for each proposal.
Sriram Vandana, Chief Financial Officer and reporting person for Quanterix Corporation (QTRX), reported a change in beneficial ownership on 08/15/2025. The filing shows a disposition of 229 shares of Quanterix common stock at a price of $4.57. The filing explains those shares were withheld by Quanterix solely to cover tax obligations upon the vesting of 777 restricted stock units (RSUs). After the reported transaction, Vandana beneficially owns 83,050 shares, which the filing notes includes 72,447 restricted stock units. The form is signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Toloue Masoud, President & CEO and director of Quanterix Corporation (QTRX), reported a transaction dated 08/15/2025 showing a disposition of 1,242 shares of common stock at a price of $4.57 per share under transaction code F. The filing explains those shares were withheld by the company to cover tax obligations related to the vesting of 3,722 restricted stock units (RSUs). After the reported transaction, the reporting person beneficially owns 514,688 shares, which the filing notes includes 228,813 restricted stock units. The form was signed by an attorney-in-fact on 08/19/2025.